BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 14535946)

  • 1. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.
    Maggio R; Scarselli M; Novi F; Millan MJ; Corsini GU
    J Neurochem; 2003 Nov; 87(3):631-41. PubMed ID: 14535946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole.
    Joyce JN; Presgraves S; Renish L; Borwege S; Osredkar T; Hagner D; Replogle M; PazSoldan M; Millan MJ
    Exp Neurol; 2003 Nov; 184(1):393-407. PubMed ID: 14637109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
    Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
    J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
    Millan MJ; Iob L; Péglion JL; Dekeyne A
    Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.
    Presgraves SP; Borwege S; Millan MJ; Joyce JN
    Exp Neurol; 2004 Nov; 190(1):157-70. PubMed ID: 15473989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
    Mierau J; Schneider FJ; Ensinger HA; Chio CL; Lajiness ME; Huff RM
    Eur J Pharmacol; 1995 Jun; 290(1):29-36. PubMed ID: 7664822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
    Perachon S; Schwartz JC; Sokoloff P
    Eur J Pharmacol; 1999 Feb; 366(2-3):293-300. PubMed ID: 10082211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
    Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
    Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
    Aloisi G; Silvano E; Rossi M; Millan MJ; Maggio R
    Neuropharmacology; 2011; 60(2-3):439-45. PubMed ID: 21035472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
    Seeman P; Ko F; Willeit M; McCormick P; Ginovart N
    Synapse; 2005 Nov; 58(2):122-8. PubMed ID: 16088951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
    Coldwell MC; Boyfield I; Brown T; Hagan JJ; Middlemiss DN
    Br J Pharmacol; 1999 Aug; 127(7):1696-702. PubMed ID: 10455328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance.
    Maggio R; Aloisi G; Silvano E; Rossi M; Millan MJ
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S2-7. PubMed ID: 20123551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D
    Ferraiolo M; Atik H; Ponthot R; Koener B; Hanson J; Hermans E
    Neuropharmacology; 2022 Apr; 207():108942. PubMed ID: 35026287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenylyl cyclase interaction with the D2 dopamine receptor family; differential coupling to Gi, Gz, and Gs.
    Obadiah J; Avidor-Reiss T; Fishburn CS; Carmon S; Bayewitch M; Vogel Z; Fuchs S; Levavi-Sivan B
    Cell Mol Neurobiol; 1999 Oct; 19(5):653-64. PubMed ID: 10384262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation.
    Novi F; Millan MJ; Corsini GU; Maggio R
    J Neurochem; 2007 Aug; 102(4):1410-24. PubMed ID: 17532788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats.
    Reavill C; Boyfield I; Coldwell M; Nelson P
    J Pharm Pharmacol; 2000 Sep; 52(9):1129-35. PubMed ID: 11045894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.